These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 30108375)
1. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Borque-Fernando Á; Rubio-Briones J; Esteban LM; Dong Y; Calatrava A; Gómez-Ferrer Á; Gómez-Gómez E; Gil Fabra JM; Rodríguez-García N; López González PÁ; García-Rodríguez J; Rodrigo-Aliaga M; Herrera-Imbroda B; Soto-Villalba J; Martínez-Breijo S; Hernández-Cañas V; Soto-Poveda AM; Sánchez-Rodríguez C; Carrillo-George C; Hernández-Martínez YE; Okrongly D Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):84-90. PubMed ID: 30108375 [TBL] [Abstract][Full Text] [Related]
2. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance. Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389 [TBL] [Abstract][Full Text] [Related]
3. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study. Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217 [TBL] [Abstract][Full Text] [Related]
4. A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer. Borque-Fernando Á; Esteban-Escaño LM; Rubio-Briones J; Lou-Mercadé AC; García-Ruiz R; Tejero-Sánchez A; Muñoz-Rivero MV; Cabañuz-Plo T; Alfaro-Torres J; Marquina-Ibáñez IM; Hakim-Alonso S; Mejía-Urbáez E; Gil-Fabra J; Gil-Martínez P; Ávarez-Alegret R; Sanz G; Gil-Sanz MJ Actas Urol Esp; 2016 Apr; 40(3):155-63. PubMed ID: 26598800 [TBL] [Abstract][Full Text] [Related]
5. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. Sugimoto M; Hirama H; Yamaguchi A; Koga H; Hashine K; Ninomiya I; Shinohara N; Maruyama S; Egawa S; Sasaki H; Kakehi Y; World J Urol; 2015 Jul; 33(7):981-7. PubMed ID: 25428792 [TBL] [Abstract][Full Text] [Related]
6. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899 [TBL] [Abstract][Full Text] [Related]
7. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance. Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755 [TBL] [Abstract][Full Text] [Related]
8. Eleven-year management of prostate cancer patients on active surveillance: what have we learned? Marenghi C; Alvisi MF; Palorini F; Avuzzi B; Badenchini F; Bedini N; Bellardita L; Biasoni D; Bosetti D; Casale A; Catanzaro M; Colecchia M; De Luca L; Donegani S; Dordoni P; Lanocita R; Maffezzini M; Magnani T; Menichetti J; Messina A; Morlino S; Paolini B; Rancati T; Stagni S; Tesone A; Torelli T; Tulli Baldoin E; Vaiani M; Villa S; Villa S; Zaffaroni N; Nicolai N; Salvioni R; Valdagni R Tumori; 2017 Sep; 103(5):464-474. PubMed ID: 28623636 [TBL] [Abstract][Full Text] [Related]
9. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447 [TBL] [Abstract][Full Text] [Related]
10. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. Punnen S; Nahar B; Prakash NS; Sjoberg DD; Zappala SM; Parekh DJ Eur Urol Focus; 2017 Feb; 3(1):94-99. PubMed ID: 28720374 [TBL] [Abstract][Full Text] [Related]
11. Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. Dai C; Ganesan V; Nyame YA; Almassi N; Greene DJ; Hettel D; Magi-Galluzzi C; Gong M; Jones JS; Stephenson AJ; Berglund RK; Klein EA Urology; 2019 Aug; 130():106-112. PubMed ID: 31071349 [TBL] [Abstract][Full Text] [Related]
12. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL. Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553 [TBL] [Abstract][Full Text] [Related]
13. Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. Wang JH; Sierra P; Richards KA; Abel EJ; Allen GO; Downs TM; Jarrard DF BMC Urol; 2019 Apr; 19(1):26. PubMed ID: 31014300 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy. Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260 [TBL] [Abstract][Full Text] [Related]
15. Statin use and time to progression in men on active surveillance for prostate cancer. Jayalath VH; Nayan M; Finelli A; Komisarenki M; Timilshina N; Kulkarni GS; Fleshner NE; Bhindi B; Evans A; Zlotta AR; Hamilton RJ Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):509-515. PubMed ID: 29875433 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. Ganesan V; Dai C; Nyame YA; Greene DJ; Almassi N; Hettel D; Zabell J; Arora H; Haywood S; Crane A; Reichard C; Zampini A; Elshafei A; Stein RJ; Fareed K; Jones JS; Gong M; Stephenson AJ; Klein EA; Berglund RK Urology; 2017 Sep; 107():184-189. PubMed ID: 28625591 [TBL] [Abstract][Full Text] [Related]
17. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance. Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398 [TBL] [Abstract][Full Text] [Related]
18. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J Eur Urol; 2024 Sep; 86(3):223-229. PubMed ID: 38772787 [TBL] [Abstract][Full Text] [Related]
19. Active surveillance for the management of prostate cancer in a contemporary cohort. Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013 [TBL] [Abstract][Full Text] [Related]
20. Multiparametric MRI in detection and staging of prostate cancer. Boesen L Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]